AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering ...

It's a threat that will send a shiver down the spine of Downing Street and shake the City of London to its core..

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...